FDA panel rejects Avastin for breast cancer, but Medicare will still pay for it -- and Provenge
( Roche Holding AG via Bloomberg News )
We've upgraded our reader commenting system. Learn more about the new features.
Los Angeles Times welcomes civil dialogue about our stories; you must register with the site to participate. We filter comments for language and adherence to our Terms of Service, but not for factual accuracy. By commenting, you agree to these legal terms. Please flag inappropriate comments.
Having technical problems? Check here for guidance.